Silver Book Fact

One economic model predicts that if type 1 and type 2 diabetics had begun Captopril (a drug that controls blood pressure and delays the onset of kidney failure) treatment in 1995, the aggregate health care cost savings in 1999 would have been $189 million and in 2004 would have been $475 million-a present value cumulative cost savings of $2.4 billion for those 10 years.

Rodby R, Firth L, Lewis E. An Economic Analysis of Captopril in the Treatment of Diabetic Nephropathy. Diabetes Care. 1996; 19(10): 1051-61. http://care.diabetesjournals.org/cgi/content/abstract/19/10/1051

Reference

Title
An Economic Analysis of Captopril in the Treatment of Diabetic Nephropathy
Publication
Diabetes Care
Publication Date
1996
Authors
Rodby R, Firth L, Lewis E
Volume & Issue
Volume 19, Issue 10
Pages
1051-61
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • A statin initiation intervention aimed at Medicare Part D prescription drug plan subscribers with diabetes or coronary artery disease was successful in increasing statin use among this group of members…  
  • DR Treatment Savings in the US
    Every year, the U.S. saves an estimated $1.6 billion by treating DR.  
  • Every additional dollar spent on the overall treatment of type 2 diabetes has produced health gains valued at $1.49.  
  • Therapy that keeps blood glucose levels as close to normal as possible in type 1 diabetics, reduces damage to the kidneys by 35-56%. Experts believe that these results can be…  
  • Evaluation of a Cooperative Extension Service diabetes education program showed improved nutrition knowledge, anthropometric measures and glucose control. These improvements reduced medical costs by approximately $94,010 for the 62 participants.